Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

Research news

Professor Colin Dayan presented with the 2023 JDRF Rumbough Award

The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.
Breakthrough T1D profile picture
Odette Myall 22 April 2024

Colin Dayan

The JDRF David Rumbough Award acknowledges an individual who has made outstanding contributions in the field of type 1 diabetes that have significantly accelerated our mission.

A leader in type 1 immunotherapy research

For over 20 years, Professor Dayan has been a leader in type 1 immunotherapy research, and his work has been central to our research strategy and overall mission. He is leading efforts to bring teplizumab, the first disease-modifying therapy approved by the US Food and Drug Administration to Europe and the UK, which would expand treatment options.

Bringing the research community together

He is a leading member of the JDRF-funded UK Type 1 Diabetes Research Consortium, through which he has brought the research community together to accelerate critical research, leverage collective resources, and collaborate to improve type 1 clinical trial delivery.

Currently, Professor Dayan serves as chair of Clinical Diabetes and Metabolism and head of section at Cardiff University School of Medicine and as part-time senior clinical researcher in the Nuffield Department of Medicine at the University of Oxford.

A profound impact

JDRF Chief Scientific Officer Sanjoy Dutta, Ph.D says: “Professor Dayan has played a significant role in advancing disease-modifying therapies for type 1 diabetes that will continue to have a profound impact on the global type 1 research community and those who are affected by the condition. JDRF is proud to honour Professor Dayan for his indelible contributions and work that supports and furthers our mission.”

Other news

Read more
Scientist researcher woman in white coat using microscope in laboratory
Research
16 May 2025

£100 million pledge by Bukhman Foundation to transform T1D research and treatment

This charitable pledge by the Bukhman Foundation represents the UK’s largest philanthropic commitment towards funding research to accelerate new treatments and a cure for type 1 diabetes.

Read more
A woman and a young man hugging while standing outside in the sun. They are wearing Breakthrough T1D t-shirts to represent Breakthrough T1D, a funder of type 1 diabetes research.
Breakthrough T1D
29 April 2025

Breakthrough T1D publishes ambitious 10-year strategy to accelerate type 1 diabetes care

We have launched a new 10-year strategy aimed at driving significant advancements in type 1 diabetes (T1D) research, treatment, and care.

Read more
Female doctor with smiling patient in clinic setting
Research
26 March 2025

Making medical research programmes and clinical trials more accessible and inclusive

Read our top takeaways from the ‘Recruiting to medical research programmes and trials – how can we be smarter and more equitable?’ webinar.

Read more
Islet cells from human donors
Research
17 March 2025

Breakthrough in T1D treatment: Improving islet transplantation

Researchers funded by Breakthrough T1D in the US have published promising new data that could help to improve islet transplantation for people with T1D.